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Methods & Materials: Ten-fold reductions of whole MTB (104
to 1 CFU/mL) in PS-MTMand PBS control were analyzed using Gen-
eXpert and real-time PCR on an ABI 7500. For Xpert evaluation of
clinical material, 50-150 L of smear-positive (3 + to1+ ) sputum
specimens (N=17) were transferred by ﬂocked swab into PS-MTM
and compared to equivalent amounts collected in PBS and routine
Xpert testing according to manufacturer’s recommendation.
Results: Using Xpert, MTB from PS-MTM was detected at 10
CFU/mL compared to 102 CFU/mL MTB detected from PBS controls.
Overall Xpert PCR efﬁciency from PS-MTM (63.2%) was improved
compared to PBS controls (34.9%). In Xpert, CT values from higher
MTB concentrations in PS-MTM were increased compared to con-
trol; however PS-MTM showed superior detection from low level
MTB concentrations. Xpert assay detected MTB from sputum col-
lected by ﬂocked swabs placed in PS-MTM in 17 of 17 specimens
and corresponded to routine Xpert detection using 1.0 mL of spu-
tum. NGS of multi-drug resistance genes was performed from the
volume remainder of ﬁve PS-MTM specimens. Resistance confer-
ring mutations for rifampicin were noted from two specimens in
the rpoB gene, which corresponded to Xpert rifampin-resistance
detection.
Conclusion: PS-MTMenhancesMTBdetectionwhen specimens
contain low level MTB. Sputum collection in PS-MTM provides safe
and inexpensive shipment/transport at ambient temperature to
centralized testing sites. Small sputum volume collected using a
ﬂocked swab allows the remaining sample to be safely archived,
re-tested, or evaluated for drug resistance by NGS.
http://dx.doi.org/10.1016/j.ijid.2016.02.840
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Background: Tuberculosis (TB) remains the most common
infection among HIV patients. Currently, the TB diagnosis is still
basedon the clinical presentation, radiographicﬁndings andmicro-
biological results. Considering the complexities of treating HIV/TB
co-infection,TB diagnosis requires the availability of diagnostic
tools that allow the rapid detection of Mycobacterium tuberculosis
complex (MTBC) and drug resistance in clinical samples.
Methods & Materials: In this retrospective study conducted
at the Instituto de Infectologia Emílio Ribas, São Paulo/BR, we
analized a total of 5350 clinical specimens (respiratory and extra-
pulmonary) collected from patients with signs and symptoms
suggestive of TB from January/14 toDecember/14. All sampleswere
processed by conventional diagnostic techniques, including smear
examination for acid-fast bacillus (AFB) and cultured in MGITF-
960 automated system. Blood and bone marrow were cultured in
BACTECFX. Identiﬁcation of MTBC and non-tuberculous mycobac-
teria (NTM) was performed by rapid immunochromatographic
assay. The average time needed for detection of mycobacteria was
15 days. Suscetibility testing for MTBC and PCR for NTM was per-
formed by Adolfo Lutz Institute, S. Paulo.
Results: Of the 5350 samples, 554 (10.35%) were positive by
culture for mycobacterial agents. Among the culture positive spec-
imens, 428 (77.25%) were from HIV-infected patients, and 342
(61.73%) were collected from male. From the 554 culture-positive
specimens, of which 398 (71.84%) respiratory and 156 (28.15%)
extra-pulmonary, 391 (70.57%) had a positive rapid test for MTBC
and 95 (17.14%) had a positive rapid test for NTM. From NTM,
Mycobacterium avium complex (MAC) was the most prevalent
(52.48%), followed by M. kansasii (15.78%) and M. fortuitum (5.26%).
Resistance was identiﬁed in 25/391 MTBC isolates (6.3%), and the
most frequently resistantdrugswere rifampicin (44%)and isoniazid
(32%), respectively.
Conclusion: TB is a important public health problem and
the diagnosis in HIV-infected patients is challenging. The use of
mycobacterial culture remains an important diagnostic tool. The
immediate future involves rapid molecular techniques, in partic-
ular GeneXpert which is also able to detect rifampicin resistance.
In order to improve diagnosis and detect as early as possible resis-
tance to rifampin, it was introduced earlier this year the GeneXpert
MTB/RIF in our hospital which proposes to be a strong diagnostic
tool for pulmonary TB.
http://dx.doi.org/10.1016/j.ijid.2016.02.841
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Background: Vitamin D enhances immune responses to tuber-
cle bacillus. The aim of our study was to demonstrate whether or
not use of cholecalciferol as supplement to patients with TB may
be improved clinical outcome.
Methods & Materials: Sixty patients with pulmonary tubercu-
losis were randomised to take either 450000 International Units
of cholecalciferol or placebo. Evaluation were carried out at one,
two and three months later. The ﬁrst outcome was reduction in
TB score and the secondary outcome was smear conversion and
improvement of quality of life. Analyseswere conductedusing SPSS
software (ver. 18) according to a pre-speciﬁed plan.
Results: Mean calcidiol levels for the whole study popula-
tion were within the insufﬁcient range (22.81±10.76 ng/ml).
There have been no associations between baseline calcidiol lev-
394 17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477
els and sputum smear burden (P-value =0.54). There was an
association of TB severity score with lower levels of Vitamin D (P-
value =0.043). The general social functioning (SF)-12 health survey
scoring at enrolment in two arms did not differ signiﬁcantly (P-
value =0.786). However two months later ﬁndings indicate that
25-hydroxyvitamin D treatment had a positive effect on progress-
ing health-related quality of life (P-value =0.019) in each subscale
of physical health score (P-value =0.028) and mental health score
(P-value =0.025).
Conclusion: Our ﬁndings indicated that high dose cholecal-
ciferol supplementation can lead to improve clinical outcome in
tuberculouspatients especially inpatientswith calcidiol deﬁciency.
Tuberculosis alleviate quality of life and necessary at TB clinics to
apply strategies to improve the health-related quality of life of TB
patients. Therefore, we recommend vitamin D supplement therapy
for this purpose.
http://dx.doi.org/10.1016/j.ijid.2016.02.842
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Background: Mycobacterium tuberculosis (M.tb) survives inside
themacrophages bymanipulating thehost immune responses.Mtb
cell-wall associated glycoproteins play an important role in initia-
tion of host-pathogen interactions.
Methods & Materials: M.smegmatis mc2155 was used in this
study. Cloning and expression was performed in pSMT3 shuttle
vector. Invasion assay in HeLa cells. Survival assay, autopahgy,
oxidative stress response, immunostaining by ﬂuroscence micro-
scope and Western blot analysis was done in mouse macrophages.
Microbial adhesion to hydrocarbons (MATH) testwas performed to
assess bacterial hydrophocity. Bacterial susceptibility against cell
wall acting antibiotics was done with CFU (Colony Forming Unit)
assay.
Results: To identify novel Mtb glycoproteins, we employed a
multi-lectin system to capture glycoproteins from puriﬁed Mtb
cell wall and identiﬁed them by mass spectrometry analysis. A
novel protein as putative acetyltransferase (ACTase)was identiﬁed.
Recombinant M.smegmatis expressing the ACTase (MsmACTase)
showed increased invasion in human epithelial cells and survival
in mouse macrophages. Increased intracellular bacillary burden
was a result of inhibition of autophagy and ROS production due
to reduced expression of superoxide dismutase (SOD) and catalase
enzymes in Msm ACTase infected macrophages when compared
with wild-type and vector control (pSMT3) strains. Subsequent
studies showed that decreased ROS production was due to over
expression of ROS scavenging peroxisomal membrane protein 70
(PMP70) . MsmACTase showed increased expression of acylCoA
oxidase (ACOX-1), a classical marker enzyme for peroxiosmal
-fatty acid oxidation. MsmACTase also exhibited increased pro-
duction of nitric oxide and expression of inducible nitric oxide
synthase (iNOS) in infected macrophages. Moreover, MsmACTase
showed increased resistance to cell wall acting anti-TB drugs and
to lysozyme due to the increased cell surface hydrophobicity.
Conclusion: We have shown that acetyltransferase gene
(ACTase) of Mtb expressed in M.smegmatis aid intracellular
mycobacterial survival through inhibition of autophagy and oxida-
tive stress responses inmacrophages. The present study reports for
the ﬁrst time thatMsm ACTase scavengesH2O2 due to over expres-
sion of ROS scavengingperoxisomalmembraneprotein 70 (PMP70)
with which insights a new mechanism how the pathogen surpass
the host defense in Mtb infection. The above ﬁndings may lead to
identiﬁcation of a potential drug target for the antimycobacterial
therapy.
http://dx.doi.org/10.1016/j.ijid.2016.02.843
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Background: To describe the overall direct medical costs and
the compensation from health insurance systems and the TB con-
trol projects, andanalyze theeconomicburden for thewhole course
of treatment of pulmonary tuberculosis (PTB) patients in Shanghai.
Methods & Materials: The copy of invoices during the course
of TB diagnosis and treatment of 766 newly registered PTB patients
from 2013 were collected in four districts in Shanghai, meanwhile
these patients were investigated by questionnaire. Descriptive
analysis and ranksum test were employed.
Results: Themedians (inter-quartile range) of 766 PTB patients’
direct medical costs for whole course of treatment were 5757.4
(3749.87, 12632.98) yuan/person. All patients had an out-patient
cost with a median of 4605.3 (3490.8, 6335.2) yuan/person, con-
sisted of the cost of western medicine (47.6%), Chinese patent
drugs (19.9%), laboratory test fee (18.1%), inspection fee (12.1%)
and treatment/registered fee (2.3%). Among the western medicine
fee, hepatoprotectants accounted for 57.1%, followed by the ﬁrst-
line anti-TB drugs (20.2%) and second-line anti-TB drug (11.1%);
a higher proportion of hepatoprotectants in Chinese patent drugs,
reached 60.8%; in laboratory test fee, costs of liver function tests
(36.2%) and tuberculosis determination (31.5%) were relatively
higher; inspection fee was mostly CT cost, accounting for 82.9%.
The amount of cost was related to the District, age, the location
of household register, health insurance types, the level of medical
institutions, categoryof PTB. Themedianof theproportionof health
